Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Inflammatory biomarkers in Alzheimer's disease plasma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Declining incidence of dementia: A national registry-based study over 20 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Lipidomics of human adipose tissue reveals diversity between body areas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blood Metabolite Signatures of Metabolic Syndrome in Two Cross-Cultural Older Adult Cohorts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lipidomic profiles, lipid trajectories and clinical biomarkers in female elite endurance athletes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • NIMA Consortium
Vis graf over relationer

INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.

METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.

RESULTS: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).

DISCUSSION: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

OriginalsprogEngelsk
TidsskriftAlzheimer's & dementia : the journal of the Alzheimer's Association
Vol/bind15
Udgave nummer6
Sider (fra-til)776-787
Antal sider12
ISSN1552-5260
DOI
StatusUdgivet - 1 jun. 2019
Eksternt udgivetJa

ID: 57306877